Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study.
Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, Zahr F, Chadderdon S, Fam N, Ong G, Yadav P, Thourani V, Vannan MA, O'Neill WW, Wang DD, Tchétché D, Dumonteil N, Bonfils L, Lepage L, Smith R, Grayburn PA, Sharma RP, Haeffele C, Babaliaros V, Gleason PT, Elmariah S, Inglessis-Azuaje I, Passeri J, Herrmann HC, Silvestry FE, Lim S, Fowler D, Webb JG, Moss R, Modine T, Lafitte S, Latib A, Ho E, Goldberg Y, Shah P, Nyman C, Rodés-Cabau J, Bédard E, Brugger N, Sannino A, Mack MJ, Leon MB, Windecker S; the TRISCEND study investigators.
Kodali S, et al. Among authors: lepage l.
Eur Heart J. 2023 Dec 7;44(46):4862-4873. doi: 10.1093/eurheartj/ehad667.
Eur Heart J. 2023.
PMID: 37930776
Tricuspid regurgitation was reduced to mild in 97.6% (P < .001), with increases in stroke volume (10.5 16.8 mL, P < .001) and cardiac output (0.6 1.2 L/min, P < .001). New York Heart Association class I or II was achieved in 93.3% (P < .001), Kansas City Cardio
…
Tricuspid regurgitation was reduced to mild in 97.6% (P < .001), with increases in stroke volume (10.5 16.8 mL, P < .001) and cardiac
…